Cangrelor Side Effects
Medically reviewed by Drugs.com. Last updated on Mar 25, 2022.
For the Consumer
Applies to cangrelor: intravenous powder for solution
Side effects requiring immediate medical attention
Along with its needed effects, cangrelor may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking cangrelor:
- Abdominal or stomach pain or swelling
- back pain
- black, tarry stools
- blood in the eyes
- blood in the urine
- bruising or purple areas on the skin
- coughing up blood
- decreased alertness
- joint pain or swelling
- Difficult or labored breathing
- tightness in the chest
- difficulty with swallowing
- fast heartbeat
- hives, itching, or rash
- large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
- noisy breathing
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- unusual tiredness or weakness
For Healthcare Professionals
Applies to cangrelor: intravenous powder for injection
The most common adverse reaction was bleeding.[Ref]
Uncommon (0.1% to 1%): Severe/life-threatening GUSTO bleeding, moderate GUSTO bleeding, any Thrombolysis in Myocardial Infarction (TIMI) bleeding, major TIMI bleeding, minor TIMI bleeding
Frequency not reported: Coronary artery dissection, coronary artery perforation[Ref]
Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) bleeding definitions:
-Severe/life-threatening GUSTO bleeding: Intracranial hemorrhage or bleeding resulting in substantial hemodynamic compromise requiring treatment.
-Moderate GUSTO bleeding: Bleeding requiring blood transfusion but not resulting in hemodynamic compromise.
-Mild GUSTO bleeding: All other bleeding not included in severe or moderate.
Thrombolysis in Myocardial Infarction (TIMI) bleeding definitions:
-Major TIMI bleeding: Any intracranial hemorrhage or any overt bleeding associated with a reduction in hemoglobin of at least 5 g/dL (if hemoglobin is not available, an absolute reduction in hematocrit of 15% or more).
-Minor TIMI bleeding: Any overt sign of bleeding (including observation by imaging techniques) associated with a reduction in hemoglobin of 3 to less than 5 g/dL (if hemoglobin is not available, an absolute reduction in hematocrit of 9% to less than 15%).[Ref]
Common (1% to 10%): Dyspnea
Frequency not reported: Bronchospasm, stridor[Ref]
Common (1% to 10%): Worsening renal function in patients with CrCl less than 30 mL/min[Ref]
Rare (less than 0.1%): Hypersensitivity
More about cangrelor
Related treatment guides
1. "Product Information. Kengreal (cangrelor)." The Medicines Company (2015):
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.